Open Access

Correction to: pH of anti-VEGF agents in the human vitreous: low impact of very different formulations

  • Bianka Sobolewska1Email author,
  • Peter Heiduschka2,
  • Karl‑Ulrich Bartz‑Schmidt1 and
  • Focke Ziemssen1
International Journal of Retina and Vitreous20173:45

https://doi.org/10.1186/s40942-017-0097-4

Received: 22 September 2017

Accepted: 6 October 2017

Published: 16 October 2017

The original article was published in International Journal of Retina and Vitreous 2017 3:22

Abstract

After the publication of this article [1], we were made aware that the osmolarity of aflibercept (Eylea) was incorrect and should have been 286 mOsm and not 1000 mOsm. The correct version of Table 1 is shown in this correction.

Correction to: Int J Retin Vitr (2017) 3:22 DOI 10.1186/s40942-017-0075-x

After the publication of this article [1], we were made aware that the osmolarity of aflibercept (Eylea) was incorrect and should have been 286 mOsm and not 1000 mOsm. The correct version of Table 1 is shown in this correction (Table 1).
Table 1

The formulations and pH values of anti-VEGF agents

Drug

Concentration (osmolarity)

Dose in the vitreous (4 ml)/dose in 0.002 ml

Formulation

Measured pH

95% CI

Ranibizumab (Lucentis)

10 mg/ml (289 mOsm)

0.5 mg/0.02 mg

10 mM histidine-HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20

5.32

5.0–5.63

Bevacizumab (Avastin)

25 mg/ml (182 mOsm)

1.25 mg/0.05 mg

42 mM NaH2PO4·H2O, 8.45 mM Na2HPO4, 6% α,α-trehalose dihydrate, 0.04% polysorbate 20

5.91

5.63–6.19

Aflibercept (Eylea)

40 mg/ml (286 mOsm)

2 mg/0.08 mg

10 mM Na3PO4, 40 mM NaCl, 5% sucrose, 0.03% polysorbate 20

6.05

5.78–6.31

Ziv-aflibercept (Zaltrap)

25 mg/ml (1000 mOsm)

1.25 mg/0.05 mg

100 mM NaCl, 5 mM Na citrate, 5 mM Na3PO4, 20% sucrose, 0.1% polysorbate 20

6.1

6.05–6.15

Rituximab (Rituxan)

10 mg/ml

1 mg/0.02 mg

154 mM NaCl, 25 mM Na citrate·2 H2O, 0.07% polysorbate 80

6.29

5.97–6.61

Notes

Declarations

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Center for Ophthalmology, Eberhard-Karl University Tübingen
(2)
Department of Ophthalmology, University of Münster Medical Center

Reference

  1. Sobolewska B et al. pH of anti-VEGF agents in the human vitreous: low impact of very different formulations. Int J Retin Vitr. 2017;3:22. doi:10.1186/s40942-017-0075-x View ArticleGoogle Scholar

Copyright

© The Author(s) 2017